Safety

Peptide Compounding: What the FDA Says About Safety

The FDA's page on bulk drug substances that may present significant safety risks when compounded, and what it says about one peptide.

By the The Peptide Finders Research Desk. Sources checked October 30, 2026. Not independently medically reviewed. Editorial standards · Request a correction

This guide is educational and is not medical advice. A listing in this directory is not a recommendation. Talk to a licensed clinician about your own situation.

The FDA's warning in general terms

The FDA says bulk drug substances used in compounding may present significant safety risks. Substances with identified risks are placed in category 2 under its interim policies.

The page is a regulatory list that changes over time, so check the current version rather than relying on this summary.

An example: ipamorelin

The FDA's category 2 entry for ipamorelin acetate cites a published study that identified serious adverse events, including death, when ipamorelin was given intravenously for improving gastric motility.

This is one entry about one route of administration in one study. Read the FDA page for the full text, and ask a clinician about any specific product.

What to ask a provider

Ask which substance is being offered, which pharmacy prepares it, how it is given, and how the clinician will monitor you. A listing here is not a statement that a product is approved or safe.

Sources

Each passage below was copied from the page named, which was opened and checked on October 30, 2026. Agency pages change, so open the link for the current text.

Related: BPC-157 research guide · CJC-1295 and ipamorelin clinics